These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30978343)

  • 1. Histone deacetylases in cardiovascular and metabolic diseases.
    Bagchi RA; Weeks KL
    J Mol Cell Cardiol; 2019 May; 130():151-159. PubMed ID: 30978343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-sirtuin histone deacetylases in the control of cardiac aging.
    Ferguson BS; McKinsey TA
    J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of histone deacetylase inhibitors on heart disease.
    Chun P
    Arch Pharm Res; 2020 Dec; 43(12):1276-1296. PubMed ID: 33245518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
    Pang M; Zhuang S
    J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
    Kee HJ; Kook H
    J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
    Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
    Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology and therapeutic implications of HDACs in the heart.
    McKinsey TA
    Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
    Christensen DP; Dahllöf M; Lundh M; Rasmussen DN; Nielsen MD; Billestrup N; Grunnet LG; Mandrup-Poulsen T
    Mol Med; 2011; 17(5-6):378-90. PubMed ID: 21274504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting histone deacetylases for heart failure.
    Bush EW; McKinsey TA
    Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylases and inhibitors in diabetes mellitus and its complications.
    Wang L; Bai Y; Cao Z; Guo Z; Lian Y; Liu P; Zeng Y; Lyu W; Chen Q
    Biomed Pharmacother; 2024 Aug; 177():117010. PubMed ID: 38941890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of selective histone deacetylase 3 inhibition.
    Zhang L; Chen Y; Jiang Q; Song W; Zhang L
    Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting histone deacetylases for heart diseases.
    Jin G; Wang K; Zhao Y; Yuan S; He Z; Zhang J
    Bioorg Chem; 2023 Sep; 138():106601. PubMed ID: 37224740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.
    Kang SH; Seok YM; Song MJ; Lee HA; Kurz T; Kim I
    Mol Pharmacol; 2015 May; 87(5):782-91. PubMed ID: 25667225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
    Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
    Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles of histone deacetylases in kidney development and disease.
    Liu H
    Clin Exp Nephrol; 2021 Mar; 25(3):215-223. PubMed ID: 33398599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatin modifications remodel cardiac gene expression.
    Mathiyalagan P; Keating ST; Du XJ; El-Osta A
    Cardiovasc Res; 2014 Jul; 103(1):7-16. PubMed ID: 24812277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.
    Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R
    Cells; 2021 May; 10(6):. PubMed ID: 34071497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
    McKinsey TA
    J Mol Cell Cardiol; 2011 Oct; 51(4):491-6. PubMed ID: 21108947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
    Raghunathan S; Goyal RK; Patel BM
    Can J Physiol Pharmacol; 2017 Mar; 95(3):260-267. PubMed ID: 28177689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.
    Wang Z; Zhao YT; Zhao TC
    Exp Biol Med (Maywood); 2021 Jan; 246(2):213-225. PubMed ID: 32727215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.